一名接受免疫检查点抑制剂治疗的子宫腺癌患者发生吉兰-巴雷综合征：病例报告及文献综述
Guillain-Barre Syndrome in a patient with uterine adenocarcinoma undergoing treatment with immune-checkpoint inhibitor therapy: A case report and review of the literature.
作者信息
Brzezinska Bogna N, Higgins Robert V, Rungruang Bunja
机构信息
Division of Gynecologic Oncology, Medical College of Georgia at Augusta University, Augusta, GA, United States.
出版信息
Gynecol Oncol Rep. 2021 Mar 2;36:100739. doi: 10.1016/j.gore.2021.100739. eCollection 2021 May.
Abstract
BACKGROUND
Use of immune checkpoint inhibitors in treatment of gynecologic malignancies is increasing. Rare, but potentially fatal, immune-related neurologic adverse events may occur as a result of treatment.
CASE
A 72 year old female with recurrent metastatic uterine adenocarcinoma received pembrolizumab and lenvatinib combination therapy. Following her second dose of pembrolizumab, the patient developed multiple neurologic symptoms. She was ultimately diagnosed with Guillain-Barre Syndrome based on neurologic evaluation with imaging, serum studies, and cerebrospinal fluid analysis. The patient was successfully treated with high-dose intravenous corticosteroids and intravenous immunoglobulin.
CONCLUSION
Neurologic complications related to immune checkpoint inhibitor therapy are rare. It is imperative for gynecologic oncologists to be familiar with potentially fatal hazards of therapy to allow for rapid diagnosis and treatment.
摘要
背景
免疫检查点抑制剂在妇科恶性肿瘤治疗中的应用日益增加。治疗可能会导致罕见但可能致命的免疫相关神经不良事件。
病例
一名72岁复发性转移性子宫腺癌女性接受了帕博利珠单抗和乐伐替尼联合治疗。在第二次注射帕博利珠单抗后，患者出现多种神经症状。最终根据影像学、血清学检查和脑脊液分析的神经评估，她被诊断为吉兰-巴雷综合征。该患者通过大剂量静脉注射皮质类固醇和静脉注射免疫球蛋白成功治愈。
结论
与免疫检查点抑制剂治疗相关的神经并发症很少见。妇科肿瘤学家必须熟悉治疗可能存在的致命风险，以便能够快速诊断和治疗。
相似文献
1
Guillain-Barre Syndrome in a patient with uterine adenocarcinoma undergoing treatment with immune-checkpoint inhibitor therapy: A case report and review of the literature.一名接受免疫检查点抑制剂治疗的子宫腺癌患者发生吉兰-巴雷综合征：病例报告及文献综述
Gynecol Oncol Rep. 2021 Mar 2;36:100739. doi: 10.1016/j.gore.2021.100739. eCollection 2021 May.
2
[Successful treatment of Guillain-Barré syndrome-like acute inflammatory demyelinating polyneuropathy caused by pembrolizumab with a combination of corticosteroid and immunoglobulins: a case report].[皮质类固醇和免疫球蛋白联合成功治疗派姆单抗引起的吉兰-巴雷综合征样急性炎症性脱髓鞘性多发性神经病：病例报告]
Rinsho Shinkeigaku. 2020 Nov 27;60(11):773-777. doi: 10.5692/clinicalneurol.cn-001444. Epub 2020 Oct 27.
3
Safe Transition to Pembrolizumab following Ipilimumab-Induced Guillain-Barré Syndrome: A Case Report and Review of the Literature.伊匹木单抗诱导的吉兰-巴雷综合征后安全过渡至帕博利珠单抗：一例病例报告及文献复习
Case Rep Oncol Med. 2019 Nov 22;2019:5490707. doi: 10.1155/2019/5490707. eCollection 2019.
4
Pembrolizumab related Guillain barre syndrome, a rare presentation in a patient with a history of lupus and bladder cancer.帕博利珠单抗相关的吉兰-巴雷综合征，在一名有狼疮和膀胱癌病史的患者中罕见表现。
J Community Hosp Intern Med Perspect. 2021 May 10;11(3):388-392. doi: 10.1080/20009666.2021.1903133. eCollection 2021.
5
Guillain-Barre syndrome induced by pembrolizumab and sunitinib: A case report.帕博利珠单抗和舒尼替尼诱发的吉兰-巴雷综合征：一例报告
Mol Clin Oncol. 2020 Jul;13(1):38-42. doi: 10.3892/mco.2020.2042. Epub 2020 May 5.
6
Complete response to pembrolizumab in a patient with metastatic colon cancer with microsatellite instability and a history of Guillain-Barre syndrome.帕博利珠单抗对一名患有微卫星不稳定的转移性结肠癌且有吉兰-巴雷综合征病史的患者产生完全缓解。
J Gastrointest Oncol. 2019 Feb;10(1):161-165. doi: 10.21037/jgo.2018.09.19.
7
Treatment Considerations for Patients with Unresectable Metastatic Melanoma Who Develop Pembrolizumab-Induced Guillain-Barré Toxicity: A Case Report.发生帕博利珠单抗诱导的吉兰-巴雷综合征毒性的不可切除转移性黑色素瘤患者的治疗考量：一例报告
Case Rep Oncol. 2020 Jan 21;13(1):43-48. doi: 10.1159/000504930. eCollection 2020 Jan-Apr.
8
Acupuncture Treatment of Guillain-Barré Syndrome After Using Immune Checkpoint Inhibitors: A Case Report.免疫检查点抑制剂治疗后格林-巴利综合征的针灸治疗：一例报告
Front Neurol. 2022 Jun 2;13:908282. doi: 10.3389/fneur.2022.908282. eCollection 2022.
9
An unusual case of recurrent Guillain-Barré syndrome with normal cerebrospinal fluid protein levels: a case report.脑脊液蛋白水平正常的复发性吉兰-巴雷综合征罕见病例：一例报告
BMC Neurol. 2016 Sep 5;16(1):161. doi: 10.1186/s12883-016-0687-z.
10
Immune Checkpoint Inhibitor-Induced Guillain Barre Syndrome: A Single-Institution Case Report and Narrative Review.免疫检查点抑制剂诱导的吉兰-巴雷综合征：单机构病例报告及叙述性综述
Cureus. 2024 Jun 1;16(6):e61489. doi: 10.7759/cureus.61489. eCollection 2024 Jun.
引用本文的文献
1
Pembrolizumab-associated Guillain-Barre syndrome in a patient with endometrial cancer: A case report.一名子宫内膜癌患者发生的帕博利珠单抗相关格林-巴利综合征：病例报告
Gynecol Oncol Rep. 2025 Jul 28;60:101816. doi: 10.1016/j.gore.2025.101816. eCollection 2025 Aug.
2
Pembrolizumab-induced Guillain-Barré syndrome in triple-negative breast cancer: A case report.帕博利珠单抗诱发三阴性乳腺癌患者吉兰-巴雷综合征：一例报告
World J Clin Oncol. 2025 Feb 24;16(2):97823. doi: 10.5306/wjco.v16.i2.97823.
3
Guillain-Barré syndrome and checkpoint inhibitor therapy: insights from pharmacovigilance data.吉兰-巴雷综合征与检查点抑制剂疗法：来自药物警戒数据的见解
BMJ Neurol Open. 2024 Mar 13;6(1):e000544. doi: 10.1136/bmjno-2023-000544. eCollection 2024.
4
A Rare Case of Paraneoplastic Guillain-Barré Syndrome in a Patient with Endometrial Cancer.子宫内膜癌患者并发副肿瘤性吉兰-巴雷综合征1例罕见病例
Eur J Case Rep Intern Med. 2023 Nov 17;10(12):004077. doi: 10.12890/2023_004077. eCollection 2023.
5
Evaluation and management of acute high-grade immunotherapy-related neurotoxicity.急性高级别免疫治疗相关神经毒性的评估与管理
Heliyon. 2023 Feb 14;9(3):e13725. doi: 10.1016/j.heliyon.2023.e13725. eCollection 2023 Mar.
6
Guillain-Barré Syndrome in the COVID-19 Pandemic.新冠疫情中的吉兰-巴雷综合征
Neurol Int. 2021 Dec 24;14(1):34-48. doi: 10.3390/neurolint14010003.
本文引用的文献
1
Guillain-Barre syndrome induced by pembrolizumab and sunitinib: A case report.帕博利珠单抗和舒尼替尼诱发的吉兰-巴雷综合征：一例报告
Mol Clin Oncol. 2020 Jul;13(1):38-42. doi: 10.3892/mco.2020.2042. Epub 2020 May 5.
2
Proposed diagnostic and treatment paradigm for high-grade neurological complications of immune checkpoint inhibitors.免疫检查点抑制剂所致高级别神经并发症的拟诊与治疗模式
Neurooncol Pract. 2019 Sep;6(5):340-345. doi: 10.1093/nop/npy039. Epub 2018 Oct 4.
3
Immune checkpoint inhibitors-induced neuromuscular toxicity: From pathogenesis to treatment.免疫检查点抑制剂诱导的神经肌肉毒性：从发病机制到治疗。
J Peripher Nerv Syst. 2019 Oct;24 Suppl 2:S74-S85. doi: 10.1111/jns.12339.
4
Immunotherapy in Gynecologic Cancers: What We Know Now and Where We Are Headed.妇科癌症中的免疫疗法：我们目前所知及未来走向
Am Soc Clin Oncol Educ Book. 2019 Jan;39:e126-e140. doi: 10.1200/EDBK_237967. Epub 2019 May 17.
5
Case Reports of Pembrolizumab-induced Acute Inflammatory Demyelinating Polyneuropathy.帕博利珠单抗诱发急性炎性脱髓鞘性多发性神经病的病例报告
Cureus. 2018 Sep 27;10(9):e3371. doi: 10.7759/cureus.3371.
6
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.免疫检查点抑制剂相关致命性毒性作用：系统评价和荟萃分析。
JAMA Oncol. 2018 Dec 1;4(12):1721-1728. doi: 10.1001/jamaoncol.2018.3923.
7
Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors.程序性细胞死亡蛋白 1（PD-1）抑制剂的神经肌肉并发症。
Curr Neurol Neurosci Rep. 2018 Aug 4;18(10):63. doi: 10.1007/s11910-018-0878-7.
8
Guillain-Barré-like syndrome during pembrolizumab treatment.帕博利珠单抗治疗期间出现吉兰-巴雷综合征样综合征。
Muscle Nerve. 2018 Feb 14. doi: 10.1002/mus.26101.
9
Neurologic complications of immune checkpoint inhibitors.免疫检查点抑制剂的神经并发症。
J Neurooncol. 2018 May;137(3):601-609. doi: 10.1007/s11060-018-2752-5. Epub 2018 Jan 13.
10
Neurologic complications of immune checkpoint inhibitors.免疫检查点抑制剂的神经系统并发症
Curr Opin Neurol. 2016 Dec;29(6):806-812. doi: 10.1097/WCO.0000000000000391.
Zotero 插件